1: Heinrich B, Brudler O, Bangerter M. [Chemotherapy is better than its reputation: important developments within the last decades]. MMW Fortschr Med. 2015 Aug 20;157(14):39-43. doi: 10.1007/s15006-015-3417-3. Review. German. PubMed PMID: 26289884.
2: Heinrich B, Brudler O, Bangerter M. [HPV associated diseases: More than warts and cervical carcinoma]. MMW Fortschr Med. 2015 May 13;157(9):41-4. doi: 10.1007/s15006-015-3082-6. Review. German. PubMed PMID: 26012825.
3: Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. PubMed PMID: 23852309.
4: Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. PubMed PMID: 23168366.
5: Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. doi: 10.1016/S1470-2045(12)70187-0. Epub 2012 May 23. PubMed PMID: 22627104.
6: Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367. PubMed PMID: 21861888; PubMed Central PMCID: PMC3173448.
7: Heinrich B, Schrembs I, Brudler O, Bangerter M. [Anemia: from symptoms to diagnosis and therapy]. MMW Fortschr Med. 2009 Nov 26;151(48):31-5; quiz 36. Review. German. PubMed PMID: 20085059.
8: Bangerter M. Cytomorphologic pitfall of primary malignant melanoma of the parotid gland: a case report. Acta Cytol. 2009 Jul-Aug;53(4):435-6. PubMed PMID: 19697731.
9: Reimer G, Brudler O, Heinrich B, Bangerter M. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy]. MMW Fortschr Med. 2008 Dec 4;150(49-50):37-8, 40. German. PubMed PMID: 19133368.
10: Bangerter M, Schmid RM. [Gastrointestinal toxicity of oncological agents]. MMW Fortschr Med. 2008 Dec 4;150(49-50):33-4, 36. German. PubMed PMID: 19133367.
11: Reimer G, Brudler O, Heinric B, Bangerter M. [Not Available]. MMW Fortschr Med. 2008 Nov;150(49):37-40. doi: 10.1007/BF03365743. German. PubMed PMID: 27372684.
12: Bangerter M, Schmid RM. [Not Available]. MMW Fortschr Med. 2008 Nov;150(49):33-6. doi: 10.1007/BF03365742. German. PubMed PMID: 27372683.
13: Bangerter M, Brudler O, Heinrich B, Schrembs I, Griesshammer M. Open or closed nuclear membrane? A question to help distinguish malignant lymphoma from carcinoma and sarcoma. Acta Cytol. 2008 Jan-Feb;52(1):52-5. PubMed PMID: 18323275.
14: Bangerter M, Brudler O, Heinrich B, Griesshammer M. Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin’s lymphoma based on the World Health Organization classification. Acta Cytol. 2007 May-Jun;51(3):390-8. PubMed PMID: 17536541.
15: Kröber A, Bloehdorn J, Hafner S, Bühler A, Seiler T, Kienle D, Winkler D, Bangerter M, Schlenk RF, Benner A, Lichter P, Döhner H, Stilgenbauer S. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006 Feb 20;24(6):969-75. Epub 2006 Jan 17. PubMed PMID: 16418492.
16: Bangerter M, Heinrich B, Brudler O. [Medical treatment of cancer in the elderly]. MMW Fortschr Med. 2004 Sep 30;146(40):30-2. Review. German. PubMed PMID: 15529665.
17: Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, Bommer M, Leithäuser F, Wawra E, Munzert G, Reske SN. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res. 2003 May 15;63(10):2681-7. PubMed PMID: 12750297.
18: Bangerter M, Hildebrand A, Griesshammer M. Combined cytomorphologic and immunophenotypic analysis in the diagnostic workup of lymphomatous effusions. Acta Cytol. 2001 May-Jun;45(3):307-12. PubMed PMID: 11393059.
19: Bangerter M, Hildebrand A, Griesshammer M. Immunophenotypic analysis of simultaneous specimens from different sites from the same patient with malignant lymphoma. Cytopathology. 2001 Jun;12(3):168-76. PubMed PMID: 11380558.
20: Griesshammer M, Bangerter M, Grünewald M. Current treatment practice for essential thrombocythaemia in adults. Expert Opin Pharmacother. 2001 Mar;2(3):385-93. Review. PubMed PMID: 11336593.
21: Bangerter M, Behnisch W, Griesshammer M. Mediastinal masses diagnosed as thymus hyperplasia by fine needle aspiration cytology. Acta Cytol. 2000 Sep-Oct;44(5):743-7. PubMed PMID: 11015973
22: Bangerter M, Güthner C, Beneke H, Hildebrand A, Grünewald M, Griesshammer M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol. 2000 Sep;65(3):165-9. PubMed PMID: 11007051.
23: Bangerter M, Hildebrand A, Waidmann O, Griesshammer M. Diagnosis of granulocytic sarcoma by fine-needle aspiration cytology. Acta Haematol. 2000;103(2):102-8. PubMed PMID: 10838454.
24: Bangerter M, Hildebrand A, Waidmann O, Griesshammer M. Fine needle aspiration cytology in extramedullary plasmacytoma. Acta Cytol. 2000 May-Jun;44(3):287-91. PubMed PMID: 10833979.
25: Griesshammer M, Kubanek B, Beneke H, Heimpel H, Bangerter M, Bergmann L, Schrezenmeier H. Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. Leuk Lymphoma. 2000 Feb;36(5-6):533-8. PubMed PMID: 10784398.
26: Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res. 1999 Nov 1;96(3):191-6. PubMed PMID: 10588461.
27: Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999;38(6):799-804. PubMed PMID: 10522771.
28: Bangerter M, Griesshammer M, Bergmann L. Progress in medical imaging of lymphoma and Hodgkin’s disease. Curr Opin Oncol. 1999 Sep;11(5):339-42. Review. PubMed PMID: 10505769.
29: Bangerter M, Griesshammer M, v Tirpitz C, Krauter J, Heil G, Hafner M, Kern W, Heiss M, Kern P. Myelodysplastic syndrome with monosomy 7 after immunosuppressive therapy in Behçet’s disease. Scand J Rheumatol. 1999;28(2):117-9. PubMed PMID: 10229142.
30: Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999 Mar;245(3):295-300. PubMed PMID: 10205592.
31: Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, Elsner K, Frickhofen N, Reske SN, Bergmann L. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998 Oct;9(10):1117-22. PubMed PMID: 9834825.
32: Griesshammer M, Arnold R, Bangerter M, Hafner M, Heinze B, Hertenstein B, Heimpel H, Bunjes D. Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol. 1998 Jul;61(1):7-13. PubMed PMID: 9688286.
33: Bangerter M, Moog F, Griesshammer M, Merkle E, Hafner M, Ellenrieder V, Reske SN, Heimpel H. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver. Int J Hematol. 1997 Dec;66(4):517-20. PubMed PMID: 9479878.
34: Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998 Feb;16(2):603-9. PubMed PMID: 9469348.
35: Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998 Feb;206(2):475-81. PubMed PMID: 9457202.
36: Griesshammer M, Heinze B, Bangerter M, Heimpel H, Fliedner TM. Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia. J Mol Med (Berl). 1997 Nov-Dec;75(11-12):836-8. PubMed PMID: 9428614.
37: Frickhofen N, Müller E, Sandherr M, Binder T, Bangerter M, Wiest C, Enz M, Heimpel H. Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood. 1997 Dec 15;90(12):4953-60. PubMed PMID: 9389714.
38: Drechsler S, Bruntsch U, Eggert J, Grote-Kiehn J, Gosse H, Bangerter M, Ukena D, Oehm C, Mezger J, Faerber L, Imhoff W, Untch M, Gallmeier WM. Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Support Care Cancer. 1997 Sep;5(5):387-95. PubMed PMID: 9322351.
39: Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997 Jun;203(3):795-800. PubMed PMID: 9169707.
40: Bangerter M, Herrmann F, Griesshammer M, Gruss HJ, Hafner M, Heimpel H, Binder T. The abundant presence of Söderström bodies in cytology smears of fine-needle aspirates contributes to distinguishing high-grade non-Hodgkin’s lymphoma from carcinoma and sarcoma. Ann Hematol. 1997 Apr;74(4):175-8. PubMed PMID: 9174545.
41: Griesshammer M, Bangerter M, Schrezenmeier H. A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia. Semin Thromb Hemost. 1997;23(5):419-23. Review. PubMed PMID: 9387200.
42: Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost. 1997;23(4):371-7. Review. PubMed PMID: 9263354.
43: Griesshammer M, Heinze B, Hellmann A, Popp C, Anger B, Heil G, Bangerter M, Heimpel H. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol. 1996 Nov;73(5):225-30. PubMed PMID: 8959940.
44: Bangerter M, Griesshammer M, Binder T, Hafner M, Heimpel H, Reske SN, Frickhofen N. New diagnostic imaging procedures in Hodgkin’s disease. Ann Oncol. 1996;7 Suppl 4:55-9. Review. PubMed PMID: 8836411.